White Matter Lesion Etiology of Dementia in the U.S. Including in Health Disparity Populations (U19 Clinical Trial not Allowed) | RFA NS 20 013

Opportunity Information: Apply for RFA NS 20 013

The grant opportunity "White Matter Lesion Etiology of Dementia in the U.S. Including in Health Disparity Populations (U19 Clinical Trial not Allowed)" (RFA-NS-20-013) is a National Institutes of Health cooperative agreement designed to fund a single large, prospective clinical research study in the United States focused on vascular contributions to cognitive impairment and dementia (VCID). The central problem it targets is that, while white matter lesions are well known to be associated with cognitive decline and dementia, researchers still do not know which features of these lesions actually drive impairment in a way that is necessary and sufficient. In practical terms, the initiative is meant to move beyond broad correlations and pinpoint the lesion volumes, anatomical locations, and cellular or molecular characteristics that most strongly and reliably predict cognitive impairment and progression to dementia.

A defining feature of the program is its emphasis on prospective, longitudinal observation in people who already have white matter lesions and are therefore at elevated risk for cognitive decline. The study is expected to map how lesion burden and lesion location relate to cognition over time, and to determine whether there are thresholds or specific brain regions where white matter damage becomes especially consequential. The language "necessary and sufficient" signals that the study should be designed to test whether certain lesion patterns are consistently present when dementia develops (necessary) and whether those patterns, on their own or in combination with a defined set of factors, can account for dementia risk (sufficient). This pushes applicants to build rigorous imaging, clinical, and analytic approaches that can distinguish mere associations from more causal or causal-like relationships.

Health disparities are not treated as an optional add-on. The study is explicitly expected to include populations experiencing health disparities and to evaluate whether the white matter lesion to cognition relationship differs across groups due to differences in exposures, comorbidities, access to care, or structural and social determinants of health. In addition, the initiative calls for careful examination of clinical factors and comorbidities that could modify the impact of white matter lesions, including factors that might be protective. That means the project should not only document vascular and metabolic risks, but also test how these risks interact with lesion characteristics to accelerate, slow, or otherwise alter cognitive trajectories.

Another major requirement is the use and advancement of "clinical trial-ready" VCID biomarkers. Rather than purely exploratory measures, the program encourages biomarkers that could realistically be deployed in future interventional trials, such as standardized neuroimaging markers, blood-based measures, or other validated indicators relevant to vascular brain injury and dementia. Applicants are encouraged to use these biomarkers as-is, to refine them further, and/or to conduct implementation research that addresses how to apply them reliably across sites and populations. This reflects a translational goal: producing measures and evidence that can directly inform the design of later prevention or treatment trials.

While the funded work itself cannot be a clinical trial, the grant is oriented toward preparing the field for trials by identifying actionable targets. Secondary goals include uncovering clinical and mechanistic targets for future VCID interventions, and clarifying how white matter lesions relate to both cerebrovascular and cardiovascular disease over time. The initiative also emphasizes understanding relationships with vascular risk factors and dementia-relevant genes, suggesting that genetic susceptibility and vascular injury should be analyzed together where feasible. The expected outcome is a clearer model of how vascular pathology, systemic vascular risk, genetics, and brain imaging findings jointly influence cognitive impairment and dementia progression.

The opportunity also encourages leveraging existing national research infrastructure to increase rigor and efficiency. Applicants are invited to make scientifically justified use of established VCID and stroke resources such as MarkVCID and StrokeNet, as well as Alzheimer’s Centers and large NIH-funded cohort studies like Framingham, ARIC, CHS, and NOMAS. The intent is to build on proven recruitment networks, standardized protocols, and existing datasets or biospecimen pipelines when that strengthens the study. This can help with enrolling diverse participants, harmonizing measurements across sites, and ensuring that findings are comparable with other major efforts in dementia and vascular brain health.

From an administrative and funding standpoint, this is a discretionary NIH cooperative agreement (U19), meaning the NIH expects substantial programmatic involvement and coordination rather than a fully investigator-driven grant with minimal oversight. The program anticipated a single award, with a very high ceiling (up to $35,000,000), reflecting the scale of the prospective study envisioned. Eligibility is broad and includes government entities, public and private universities, tribal governments and organizations, nonprofits (both 501(c)(3) and non-501(c)(3)), and for-profit organizations (other than small businesses as well as small businesses), among others as clarified in the full announcement. The sponsoring agency is the U.S. Department of Health and Human Services through the NIH, with CFDA listings 93.853 and 93.866, aligning with neurological disorders and stroke-related research missions.

Overall, the initiative is structured to deliver a definitive, clinically meaningful understanding of which white matter lesion features matter most for dementia risk, how those effects vary across populations including groups facing health disparities, and which biomarkers and mechanistic pathways are most ready to be carried forward into future VCID interventional trials. The intended deliverables are not just publications, but a stronger evidentiary and methodological foundation for prevention and treatment strategies that address vascular contributions to dementia in real-world U.S. populations.

• The Department of Health and Human Services, National Institutes of Health in the health sector is offering a public funding opportunity titled "White Matter Lesion Etiology of Dementia in the U.S. Including in Health Disparity Populations (U19 Clinical Trial not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853, 93.866.
• This funding opportunity was created on Dec 30, 2019.
• Applicants must submit their applications by Mar 31, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $35,000,000.00 in funding.
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).

Apply for RFA NS 20 013

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: